Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:41:05.657Z.
Calculation as of: 2026-10-06T19:41:05.657Z.
Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 273f4a35489c6dcba82bfbf6813c8f243fa8fa5e32baf23fc33ea9a1b57f5f97
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Compass Therapeutics, Inc.
Market Cap
$181.55M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$180.31M
Price/FCF Ratio
N/A
TTM Avg
28.71
3Y Avg
28.66
5Y Avg
28.66
Market Cap
$182.41M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$187.18M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$174.81M
Price/FCF Ratio
N/A
TTM Avg
26.11
3Y Avg
26.11
5Y Avg
26.11
Market Cap
$170.78M
Price/FCF Ratio
N/A
TTM Avg
81.50
3Y Avg
61.57
5Y Avg
61.57
Market Cap
$170.85M
Price/FCF Ratio
N/A
TTM Avg
396.65
3Y Avg
396.65
5Y Avg
396.65
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | $181.55M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $180.31M | N/A | 28.71 | 28.66 | 28.66 |
| Canton Strategic Holdings Inc (CNTN)vs › | $182.41M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.78M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $187.18M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $175.95M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $174.81M | N/A | 26.11 | 26.11 | 26.11 |
| Journey Medical Corporation (DERM)vs › | $170.78M | N/A | 81.50 | 61.57 | 61.57 |
| Precision BioSciences, Inc. (DTIL)vs › | $170.85M | N/A | 396.65 | 396.65 | 396.65 |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $191.14M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
